Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX + tislelizumab + donafenib perioperative therapy for high‑risk resectable intrahepatic cholangiocarcinoma
ChiCTR2500112067Phase 2Not yet recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, donafenib, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Hunan Provincial People's Hospital. Primary endpoint: Event-free survival (EFS). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tislelizumabdonafenibgemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500112067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112067.